LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, A. Antón Torres, Giampaolo Bianchini, E. Sevillano Fernandez, Stefania Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Riccardo Spezia, Hoda Ali, Giuseppe Viale